Flatiron Health has announced the expansion of their real-world evidence (RWE) offerings, leveraging the high-quality foundational real-world data (RWD) assets that the company is well known for.
The Integrated RWE Solutions includes analytic, scientific, and consultative services, providing customers with a more flexible way to engage with Flatiron. Having established itself as an important oncology RWD partner for many pharmaceutical companies, this expansion establishes an expert, one-stop-shop for oncology RWD/E generation, delivering oncology evidence solutions tailored to fit customers’ unique needs.
The Integrated RWE Solutions approach also minimises risks associated with RWD studies, as the professionals executing these studies have a deep understanding of the complexities and nuances of the oncology EHR as applied to the development of the RWE.
Flatiron’s RWD integrates through OncoEMR, an intuitive EMR software built by and for community oncologists, which allows data to be auditable and traceable back to source documents. This ability to operate as a fully integrated solution, provides oncology physicians and clinicians with a way to oversee data curation methods and lead the development of complex data variables appropriate for oncology research. Flatiron generates high-quality data with the depth required for most oncology evidence generation needs, through a combination of machine learning and human approaches.
“This is a natural and exciting evolution for Flatiron. As experts in data extraction from our clinical EHR and deep curation for life sciences research, we’ve developed extensive “data empathy,” a multi-faceted, detailed knowledge and understanding of oncology EHR data. During that time, we’ve also built a world-class team of oncologists, researchers, and health data analysts who understand the intricacies of RWE generation for oncology,” said Stephanie Reisinger, SVP & General Manager, Real-World Evidence.
Click here to read the original news story.
Flatiron Health has announced the expansion of their real-world evidence (RWE) offerings, leveraging the high-quality foundational real-world data (RWD) assets that the company is well known for.
The Integrated RWE Solutions includes analytic, scientific, and consultative services, providing customers with a more flexible way to engage with Flatiron. Having established itself as an important the oncology RWD partner of choice for many pharmaceutical companies, this expansion establishes an expert, one-stop-shop for oncology RWD/E generation, delivering oncology evidence solutions tailored to fit customers’ unique needs.
The Integrated RWE Solutions approach also minimises risks associated with RWD studies, as the professionals executing these studies have a deep understanding of the complexities and nuances of the oncology EHR as applied to the development of the RWE.
Flatiron’s RWD integrates through OncoEMR, an intuitive EMR software built by and for community oncologists, which allows data to be auditable and traceable back to source documents. This ability to operate as a fully integrated solution, provides oncology physicians and clinicians with a way to oversee data curation methods and lead the development of complex data variables appropriate for oncology research. Flatiron generates high-quality data with the depth required for most oncology evidence generation needs, through a combination of machine learning and human approaches.
“This is a natural and exciting evolution for Flatiron. As experts in data extraction from our clinical EHR and deep curation for life sciences research, we’ve developed extensive “data empathy,” a multi-faceted, detailed knowledge and understanding of oncology EHR data. During that time, we’ve also built a world-class team of oncologists, researchers, and health data analysts who understand the intricacies of RWE generation for oncology,” said Stephanie Reisinger, SVP & General Manager, Real-World Evidence.
Click here to read the original news story.